Atlas Trials

A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).

Clinical trial NCT05953909 · UNKNOWN

Trial details

NCT number
NCT05953909
Sponsor
Fujian Cancer Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
Breast Cancer
Start date
2023-02-01
Primary completion
2023-08-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.